Xeljanz

Xeljanz Under Safety Review for Health Canada

Xeljanz Linked to Increased Rick of Serious Heart-Related Issues and Cancer

 

Written by: Lauren Schwab, Legal Assistant

Law Offices of Thomas J. Lamb, P.A.

 

Xeljanz, a popular drug used to treat moderate to severe rheumatoid arthritis as well as moderate to severe ulcerative colitis, is under evaluation by Health Canada after results from a clinical trial showed links between the drug and serious heart-related issues and cancer.

This is not the first time Xeljanz has been under review by Health Canada, however. In 2019, Xeljanz was linked to an increased risk of blood clots in the lungs and potentially death following the publication of the results of a clinical trial. Health Canada and the drug manufacturing company, Pfizer, worked together to update both the Xeljanz and Xeljanz XR label to include thrombosis in the warnings section.

 

__________________________________________________________________

Xel­janz

Free Case Evaluation

Strictly Confidential, No Obligation.

__________________________________________________________________

 

According to the April 6, 2021 Canadian safety alert, Pfizer and Health Canada are once again working together to evaluate the safety of Xejanz and Xeljanz XR:

The clinical trial investigated the long-term safety of Xeljanz and Xeljanz XR (tofacitinib) at two doses (5 mg twice a day and 10 mg twice a day) in patients with rheumatoid arthritis, who are at least 50 years of age and have at least one cardiovascular risk factor. Pfizer, the manufacturer of the drug, conducted the trial in multiple countries, including Canada.

The current Canadian label includes serious warnings and precautions for cancer and information on heart attacks, which were the most frequently reported serious heart-related problems in this trial.

Health Canada has not authorized the sale of the higher dose of 10 mg twice a day for rheumatoid arthritis or psoriatic arthritis; this dose is only authorized for patients with ulcerative colitis who have not responded well to other medications. For patients with ulcerative colitis, the Canadian prescribing information recommends that they use the lowest effective dose possible to lower the risk of adverse reactions.

As previously mentioned on our February 2021 Drug Injury Watch blog article, "Xeljanz Has A New Drug Safety Issue, We Just Don't Know How Significant It Is, Yet", in the U.S., many experts are advocating for more research on the long-term effects of Xeljanz:

In our recent post, "Xeljanz FDA Drug Safety Communication in February 2021 Puts Heightened Scrutiny on Pfizer", we touched upon the two latest Xeljanz safety issues, Xeljanz causing heart problems and Xeljanz causing cancer. But there is still a lot that we do not know, yet, about how significant this new drug safety issue, or will be, for Xeljanz -- and Pfizer, the pharmaceutical company responsible for Xeljanz.

Be assured that we will continue to follow their coverage of Xeljanz as well as watch for possible FDA regulatory action concerning Xeljanz and Xeljanz XR.

 

Drug Injury WatchSide Effects News & Reports

Drug Injury Law: Medical & Legal Information


April 16, 2021

February 08, 2021

February 05, 2021

Search Engine

  • Google

    WWW
    www.drug-injury.com

Patient Advisory

  • The prescription drugs discussed on this site are approved for use by the the Food and Drug Administration (FDA). Patients should not stop taking any prescription drug without seeking the advice of their medical doctor. This site is not affiliated with any of the drug companies or the FDA.

Quick Contact Form

  • In a rush? You can use our Quick Contact Form to tell us the basic facts about your case.

Free Case Evaluation


  • We encourage you to submit a Drug Injury Legal Case Evaluation – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience handling drug injury lawsuits.

Drug Injury Watch

Thank You For Reading


Subscribe to Lamb Law Office Newsletter

Subscribe to our Lamb Law Office Newsletter for periodic updates about some of the cases we are working on for clients. We include, also, an information resource you might find helpful in each Newsletter.

* indicates required